JMP keeps Myriad at strong buy rating

Myriad Genetics, Inc. was reiterated by JMP Securities analyst Charles C. Duncan at a strong buy rating with a $33 price target. The company reported quarterly results that met both the analyst's and consensus revenue estimates with solid growth in Predictive Medicine (PM) revenue. Myriad's net loss of $0.31 per share was slightly higher than Duncan's and consensus expectations of $0.30 and $0.28 per share, respectively. PM revenues of $30.9 million in the first-quarter 2007 were directly in line JMP's estimates and up 7% from last quarter. Shares of the Salt Lake City biopharmaceutical company were down 12 cents, or 0.42%, at $28.56. (Nasdaq: MYGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.